PMDA drug package insert
インフリキシマブBS点滴静注用100mg「NK」
PMDA Prescription drug · セルトリオン・ヘルスケア・ジャパン株式会社 · package insert Jun 17, 2026
Key facts
| Brand names | インフリキシマブBS点滴静注用100mg「NK」 |
|---|---|
| Nonproprietary names | インフリキシマブ（遺伝子組換え） |
| Companies | 製造販売元／セルトリオン・ヘルスケア・ジャパン株式会社, 販売／日本化薬株式会社 |
| Product type | Prescription drug |
| Therapeutic category | 抗ヒトTNFαモノクローナル抗体製剤 |
| Therapeutic category codes | 87239 |
| YJ codes | 2399403F1039 |
| Approval numbers | 22600AMX00758 |
| Package insert edition | 第10版 |
| Package insert date | Jun 17, 2026 |
| PMDA document key | 381103_2399403F1039_2 |
| PMDA company code | 381103 |
At a glance
- 1–9 Package insert revisions
- 10–99 Related PMDA documents
- 1–9 Safety communications
- Yes PMDA review report published
- No Risk management plan (RMP)
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About PMDA approved drugs and package inserts (Japan)
Japan's PMDA publishes the package insert (添付文書) of every prescription drug, OTC drug and regenerative medical product, with brand and nonproprietary names, YJ codes and approval numbers. Names appear in Japanese as published.
Source: Pharmaceuticals and Medical Devices Agency (PMDA), Japan, package insert database · Source date: